Table 2.

PD-L1 fractional abundance (FA) in plasma-derived MVs at baseline and at first tumor assessment (3 months) vs. tumor response in patients treated with GEMnPAC or FOLFIRINOX.

GEMnPAC Group					FOLFIRINOX Group
Patient	PD-L1 FA (Baseline)	PD-L1 FA (3 Months)	PD-L1 FA Change	Tumor Response	Patient	PD-L1 FA (Baseline)	PD-L1 FA (3 Months)	PD-L1 FA Change	Tumor Response
1	0.007	0.005	↓	PR	35	0.007	0.004	↓	SD
2	0	0.005	↑	SD	36	0.018	0.007	↓	PR
3	0	0	=	PR	37	0	0	=	PD
4	0.007	0.014	↑	SD	38	0	0.007	↑	PD
5	0.004	0.007	↑	SD	39	0.001	0	↓	SD
6	0.009	0.009	=	PD	40	0	0.009	↑	SD
7	0.002	0.012	↑	PR	41	0	0	=	SD
8	0	0.002	↑	PD	42	0	0	=	SD
9	0.005	0.003	↓	PD	43	0.009	0.003	↓	PR
10	0	0.017	↑	PD	44	0	0.009	↑	PD
11	0.002	0.008	↑	SD	45	0.007	0.006	↓	SD
12	0.003	0.005	↑	SD	46	0.017	0.006	↓	SD
13	0.005	0.003	↓	SD	47	0.006	0.01	↑	SD
14	0.015	0.003	↓	SD	48	0.005	0.006	↑	SD
15	0.004	0	↓	SD	49	0.003	0.003	=	PD
16	0.008	0.004	↓	PD	50	0.004	0.004	=	SD
17	0	0	=	PR
18	0.008	0.006	↓	SD
19	0	0.018	↑	SD
20	0	0	=	PD
21	0	0.016	↑	PR
22	0.001	0	↓	PD
23	0	0.004	↑	PR
24	0	0.009	↑	SD
25	0	0.019	↑	SD
26	0	0	=	SD
27	0	0.011	↑	PR
28	0	0.003	↑	PR
29	0.003	0.001	↓	PR
30	0.002	0.015	↑	PD
31	0	0	=	SD
32	0	0.005	↑	SD
33	0.004	0.006	↑	SD
34	0.005	NE	NE	PD

Abbreviations: ↑, increase; ↓, decrease; =, no variation; NE, not evaluable.